Statins for people at low risk of cardiovascular disease

The Lancet

Volumn 380, Issue 9856, 2012, Pages 1814-1815

  Donzelli, Alberto ^a  

^a Servizio Educazione all'Appropriatezza ed EBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; HUMAN; LETTER; LOW RISK POPULATION; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; UNSPECIFIED SIDE EFFECT; BLOOD; NOTE; VASCULAR DISEASE;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; VASCULAR DISEASES;

EID: 84869432250     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62021-2     Document Type: Letter

References (3)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
2. Therapeutics Initiative. Do statins have a role in primary prevention? An update. Therapeutics Letter 2010; 77: 1-5.
3. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336: 601.